Mohamed Sagad O O, Ahmed Hussein, Mohammednoor Mohammed A H, Alzubeir Khalefa B K, Fadlelmoula Safaa, Abdallah Osman O A, Ahmed Izzut Awad
Faculty of Medicine, University of Khartoum, Alqasr Avenue, P.O. Box 102, Khartoum, Sudan.
Thyroid Res. 2025 Feb 3;18(1):3. doi: 10.1186/s13044-024-00220-9.
There has been an increasing comprehension and recognition of endocrine dysfunction among both pediatric and adult patients with sickle cell disease (SCD). Thyroid disorders can have significant clinical consequences, including growth retardation and impaired cognitive function. However, there is a disparity in the available data concerning the magnitude and spectrum of thyroid abnormalities in this population. This review aimed to provide a systematic summary and analyses on the status of thyroid function abnormalities in individuals with SCD.
Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, a comprehensive search was conducted across Medline/PubMed, Google Scholar, World Health Organization Virtual Health Library Regional Portal, and ScienceDirect. Pooled prevalence and standardized mean difference (SMD) estimates with 95% confidence intervals (CIs) were calculated using Comprehensive Meta-Analysis Software version 3.3.
Nineteen studies met the inclusion criteria and were incorporated into the analyses. Serum thyroid-stimulating hormone (TSH) levels were significantly higher in SCD patients compared to controls (SMD = 1.184; 95% CI, 0.269-2.099; p = 0.011). While non-significant, there was a trend towards lower levels of triiodothyronine (T3), thyroxin (T4), free T3, and free T4 in the SCD group (T3: SMD = -1.746; 95% CI, -3.561-0.070; p = 0.059; T4: SMD = -1.365; 95% CI, -3.030-0.300; p = 0.108; free T3: SMD = -0.384; 95% CI, -1.128-0.356; p = 0.311; free T4: SMD = -1.205; 95% CI, -2.522-0.111; p = 0.073). The pooled prevalence of hypothyroidism and subclinical hypothyroidism among SCD patients was found to be 4.9% and 8.7%, respectively.
Individuals with SCD exhibit a tendency towards elevated TSH levels compared to the general population, with a subset potentially developing thyroid abnormalities, particularly subclinical hypothyroidism. Although not highly prevalent in the SCD population, monitoring thyroid function remains essential due to the potential for progression to overt hypothyroidism and its associated adverse health outcomes.
镰状细胞病(SCD)的儿童和成人患者对内分泌功能障碍的理解和认识日益增加。甲状腺疾病可产生重大临床后果,包括生长发育迟缓及认知功能受损。然而,关于该人群甲状腺异常的程度和范围,现有数据存在差异。本综述旨在对SCD患者甲状腺功能异常状况进行系统总结和分析。
按照系统评价和Meta分析的首选报告项目(PRISMA)指南,在Medline/PubMed、谷歌学术、世界卫生组织虚拟健康图书馆区域门户及ScienceDirect数据库进行全面检索。使用综合Meta分析软件3.3计算合并患病率及95%置信区间(CI)的标准化均数差(SMD)估计值。
19项研究符合纳入标准并纳入分析。与对照组相比,SCD患者血清促甲状腺激素(TSH)水平显著更高(SMD = 1.184;95% CI,0.269 - 2.099;p = 0.011)。虽然差异无统计学意义,但SCD组三碘甲状腺原氨酸(T3)、甲状腺素(T4)、游离T3和游离T4水平有降低趋势(T3:SMD = -1.746;95% CI,-3.561 - 0.070;p = 0.059;T4:SMD = -1.365;95% CI,-3.030 - 0.300;p = 0.108;游离T3:SMD = -0.384;95% CI,-1.128 - 0.356;p = 0.311;游离T4:SMD = -1.205;95% CI,-2.522 - 0.111;p = 0.073)。SCD患者中甲状腺功能减退和亚临床甲状腺功能减退的合并患病率分别为4.9%和8.7%。
与一般人群相比,SCD患者呈现TSH水平升高的趋势,一部分患者可能出现甲状腺异常,尤其是亚临床甲状腺功能减退。尽管在SCD人群中患病率不高,但鉴于其有进展为显性甲状腺功能减退及其相关不良健康后果的可能性,监测甲状腺功能仍然至关重要。